Frequently Asked Questions

Can I qualify for financial assistance if I am currently covered by a commercial (private) health insurance plan?

Yes, patients with commercial insurance can qualify for help from the JETREA CARE® CO-PAY ASSISTANCE PROGRAM.

Click here for more details and to find out how to enroll.

Back to top

Can I qualify for financial assistance if I am currently covered by Medicare or other government insurance?

Yes, patients with Medicare and other government sponsored insurance can qualify for help from independent nonprofit foundations. JETREA CARE® can help refer qualifying patients to appropriate independent nonprofit foundations.

Click here for more details and to find out how to enroll.

Back to top

If I qualify, how will JETREA CARE® assist?

JETREA CARE® CO-PAY ASSISTANCE PROGRAM can help qualifying patients with commercial insurance pay no more than $25 for the cost of JETREA® that is not covered by their insurance, including co-pay or co-insurance, and/or deductible* – click here to find out more details.

JETREA CARE® can refer qualifying patients covered by Medicare or other government sponsored insurance to independent nonprofit foundations** which can offer co-pay assistance – click here to find out more details.

JETREA CARE® can help qualified uninsured patients to receive JETREA at no cost – click here to find out more details.

*JETREA CARE® CO-PAY ASSISTANCE PROGRAM does not apply to patient financial responsibility for the injection procedure. Co-pay assistance is capped at $2,000. Patients with any remaining balance will be referred to a nonprofit foundation.

**Independent nonprofit foundations provide assistance regardless of the choice of medicine, and decisions are based on financial need and according to criteria established by individual foundations. JETREA CARE® can assist patients by referring them to these independent nonprofit foundations. Neither ThromboGenics® nor JETREA CARE® can guarantee that patients will be eligible for or receive co-pay assistance after referral. Neither ThromboGenics® nor JETREA CARE® have controlling or managerial influence on these independent nonprofit foundations.

Back to top

How do I enroll in one of the JETREA CARE® co-pay or financial assistance options?

Talk to your doctor’s office to enroll in the program that is right for you. Your doctor’s office will complete the enrollment form and submit it to JETREA CARE®.

Back to top

I’m not comfortable with sharing my household income with my doctor’s office; can I give this information directly to JETREA CARE®?

Your household income information is necessary to determine if you qualify for a financial assistance program offered through JETREA CARE®.

Patients with government-sponsored insurance will be required to provide income information directly to the independent nonprofit foundation.

If you prefer to keep your income confidential, you can provide this information directly to JETREA CARE® at (855) TRY-JETREA (879-5387) [Option 1] (Monday through Friday, 7AM to 7PM CST).

Back to top

How will I know if I have been approved for financial assistance?

Qualifying patients will receive an approval letter for the JETREA CARE® CO-PAY ASSISTANCE PROGRAM or the JETREA CARE® Patient Assistance Program. Approval notification will also be sent to your doctor’s office.

Patients approved for the JETREA CARE® CO-PAY ASSISTANCE PROGRAM will be required to provide an explanation of benefits (EOB) verifying their financial responsibility (funds will be released upon submission).

Qualifying patients covered by Medicare or other government sponsored insurance and their doctors will be contacted directly by an appropriate independent nonprofit foundation with more information regarding their application, required documentation, and approval status.

Back to top

What happens after I receive my approval letter?

Once you have been approved, talk to your doctor to schedule your appointment and receive treatment with JETREA.

Make sure to bring your approval notice from JETREA CARE® or the independent co-pay foundation to your doctor on the day of your treatment.

Back to top

Indication

JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of
symptomatic vitreomacular adhesion.

Important Safety Information

Warnings and Precautions

  • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
  • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
  • Potential for lens subluxation.
  • In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.
  • Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).

Adverse Reactions

  • The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

Please see full Prescribing Information for JETREA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Patient.